An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer
Vandross, Andrae L., Stein, Brian N., Coward, Jermaine, Sharma, Sunil, Johnson, Amy J., Birkett, Joseph, Huang, Xin, Frigault, Melanie M., Lerchen, Hans-georg, Stelte-Ludwig, Beatrix, Navarro, Tasheda, Peck, Jim, Gross, Wyatt, Izumi, Raquel, Hamdy, Ahmed M., Rodriguez Rivera, Ildefonso
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies
Strickland, Stephen Anthony, Curran, Emily K., Jamy, Omer Hassan, Percival, Mary-Elizabeth, Johnson, Amy J., Birkett, Joseph, Huang, Xin, Frigault, Melanie M., Lerchen, Hans-georg, Stelte-Ludwig, Beatrix, Navarro, Tasheda, Peck, Jim, Gross, Wyatt, Izumi, Raquel, Hamdy, Ahmed M., Daver, Naval Guastad
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile
Byrd, John C., Wierda, William, Jones, Jeffrey, O'Brien, Susan, Brown, Jennifer R., Schuh, Anna, Hillmen, Peter, Stephens, Deborah M., Ghia, Paolo, Devereux, Steve, Chaves, Jorge M., Barrientos, Jacqueline C., Wang, Min Hui, Huang, Jane, Covey, Todd, Navarro, Tasheda, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Furman, Richard R.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study
O'Brien, Susan Mary, Barrientos, Jacqueline Claudia, Flinn, Ian W., Barr, Paul M., Burger, Jan Andreas, Navarro, Tasheda, James, Danelle Frances, Hedrick, Eric, Friedberg, Jonathan W., Brown, Jennifer R.
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study
Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan Andreas, Blum, Kristie A., Sharman, Jeff Porter, Flinn, Ian W., Grant, Barbara W., Heerema, Nyla A., Johnson, Amy J, Navarro, Tasheda, James, Danelle Frances, Hedrick, Eric, O'Brien, Susan Mary
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study
O'Brien, Susan, Burger, Jan A., Blum, Kristie A., Furman, Richard R., Coutre, Steven E., Sharman, Jeff, Flinn, Ian W., Grant, Barbara, Heerema, Nyla A., Johnson, Amy J., Navarro, Tasheda, Holmgren, Eric, Hedrick, Eric, Byrd, John C.
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases
Jaglowski, Samantha Mary, Jones, Jeffrey Alan, Flynn, Joseph M., Andritsos, Leslie A., Maddocks, Kami J., Blum, Kristie A., Grever, Michael R., Geyer, Susan Michelle, Woyach, Jennifer Ann, Johnson, Amy J, Heerema, Nyla A., Molnar, Erin, Stefanos, Mona, Devlin, Susan, Navarro, Tasheda, James, Danelle Frances, Lowe, Ann M., Hedrick, Eric, Byrd, John C.
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article